COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine with a focus on non-animal-derived rhCollagen technology, has announced it will release its first quarter 2025 financial results on Wednesday, May 28, 2025, before U.S. markets open. The company develops innovative technologies and products for tissue regeneration and medical aesthetics applications.

News Market Reaction – CLGN

+5.48%

+5.48% Session move

In the trading session that priced this news, CLGN gained 5.48%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com

Contacts:
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com

Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com 

Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-first-quarter-financial-results-302455030.html

SOURCE CollPlant

FAQ

When will CollPlant Biotechnologies (CLGN) report Q1 2025 earnings?

CollPlant Biotechnologies will report its Q1 2025 financial results on Wednesday, May 28, 2025, before the U.S. financial markets open.

What is CollPlant Biotechnologies' (CLGN) main business focus?

CollPlant Biotechnologies focuses on regenerative and aesthetics medicine, developing innovative technologies and products based on non-animal-derived rhCollagen for tissue regeneration and medical aesthetics.

What stock exchange is CollPlant Biotechnologies (CLGN) listed on?

CollPlant Biotechnologies is listed on the NASDAQ stock exchange under the ticker symbol CLGN.

What type of collagen technology does CollPlant (CLGN) use?

CollPlant uses non-animal-derived rhCollagen technology for its products and innovations.